Screener
Becton, Dickinson and Company BDX Medical Essentials — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Becton, Dickinson and Company in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:34 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000010795-26-000026
| Three Months Ended March 31, 2026 / (Millions of dollars) | Medical / Essentials | Connected / Care | Bio Pharma / Systems | Interventional | Total |
|---|---|---|---|---|---|
| % of revenues | 50.7% | 43.7% | 53.6% | 31.6% | |
| Selling and administrative expense | 185 | 190 | 32 | 277 | 684 |
| % of revenues | 11.2% | 17.0% | 5.4% | 20.4% | |
| Research and development expense | 53 | 90 | 17 | 72 | 232 |
| % of revenues | 3.2% | 8.1% | 2.8% | 5.3% | |
| Other operating expense, net | — | 3 | — | — | 3 |
| % of revenues | — | 0.3% | — | — | |
| Segment Operating Income | $574 | $347 | $225 | $579 | $1,724 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Becton, Dickinson and Company's medical essentials — research and development expense?
- Becton, Dickinson and Company (BDX) reported medical essentials — research and development expense of $53M in Q1 2026.
- What does medical essentials — research and development expense mean?
- This metric captures the investment made by the Medical Essentials segment into research and development activities, including new product innovation and enhancements to existing medical devices. It reflects the segment's commitment to long-term growth and technological advancement.
Ask your AI about Becton, Dickinson and Company's medical essentials — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude